9.05

1.46% 0.13

Pre-market: 9.00 -0.05 -0.55%

Corbus Pharmaceuticals Holdings Inc (CRBP)

Overview News Price History Financials Discussions Forecast Stock Split

Corbus Pharmaceuticals Holdings Inc stock is traded at $9.05, with a volume of 138.00K. It is up +1.46% in the last 24 hours and up +0.78% over the past month. Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Previous Close:

$8.92

Open:

$8.9

24h Volume:

138.00K

Relative Volume:

0.29

Market Cap:

$167.68M

Revenue:

$1.54M

Net Income/Loss:

$-84.53M

P/E Ratio:

-1.5565

EPS:

-5.8145

Net Cash Flow:

$-73.65M

1W Performance:

-2.90%

1M Performance:

+0.78%

6M Performance:

+9.43%

1Y Performance:

-2.27%

1-Day Range:

$8.79

$9.36

1-Week Range:

$8.78

$9.54

52-Week Range:

$7.12

$20.56

Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile

Name

Corbus Pharmaceuticals Holdings Inc

Sector

Healthcare (1076)

Industry

Biotechnology (598)

Phone

617-963-0103

Address

500 RIVER RIDGE DRIVE, NORWOOD, MA

Employee

Twitter

@corbuspharma

Next Earnings Date

2026-08-04

Latest SEC Filings

CRBP's Discussions on Twitter

Compare CRBP vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRBP Corbus Pharmaceuticals Holdings Inc	9.05	168.23M	1.54M	-84.53M	-73.65M	-5.8145
VRTX Vertex Pharmaceuticals Inc	481.70	121.57B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	738.34	69.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	872.58	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	192.17	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	322.08	33.81B	5.76B	514.49M	1.10B	4.4813

Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-30-25	Resumed	B. Riley Securities	Buy
Feb-28-25	Initiated	William Blair	Outperform
Dec-02-24	Initiated	Piper Sandler	Overweight
Jul-30-24	Initiated	Wedbush	Outperform
Jul-22-24	Resumed	H.C. Wainwright	Buy
Jun-26-24	Initiated	B. Riley Securities	Buy
Jun-03-24	Reiterated	Oppenheimer	Outperform
May-13-24	Initiated	RBC Capital Mkts	Outperform
Mar-06-24	Upgrade	Jefferies	Hold → Buy
Sep-08-20	Downgrade	BTIG Research	Buy → Neutral
Sep-08-20	Downgrade	Jefferies	Buy → Hold
Sep-08-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-08-20	Downgrade	ROTH Capital	Buy → Neutral
Jul-07-20	Initiated	ROTH Capital	Buy
Jun-17-20	Initiated	BTIG Research	Buy
Mar-26-20	Initiated	Nomura	Buy
Apr-05-19	Initiated	Jefferies	Buy
Mar-20-19	Initiated	Oppenheimer	Outperform
Jan-11-19	Reiterated	Cantor Fitzgerald	Overweight
Dec-26-18	Initiated	H.C. Wainwright	Buy
Dec-07-18	Initiated	RBC Capital Mkts	Outperform
Oct-24-18	Initiated	B. Riley FBR	Buy
Jan-19-18	Initiated	Raymond James	Outperform
Dec-14-17	Reiterated	Cantor Fitzgerald	Overweight
Nov-08-17	Reiterated	Noble Financial	Buy
Sep-29-17	Resumed	Noble Financial	Buy
Mar-30-17	Reiterated	Cantor Fitzgerald	Overweight
Nov-15-16	Reiterated	JMP Securities	Mkt Outperform
Nov-11-16	Reiterated	Noble Financial	Buy

View All

Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News

Jul 28, 2026

Corbus Pharmaceuticals (CRBP) Gains FDA Nod for Pivotal CRB-701 - GuruFocus

Jul 28, 2026

Corbus Pharmaceuticals Holdings, Inc. initiates FDA-cleared registrational study for CRB-701 in oropharyngeal cancer - Traders Union

Jul 28, 2026

FDA clears Corbus registrational trial for head and neck cancer drug - Investing.com Canada

Jul 28, 2026

Corbus Pharmaceuticals Announces FDA Clearance to Initiate - GlobeNewswire

Jul 28, 2026

Jul 27, 2026